Free Trial

MetLife (MET) Stock Forecast & Price Target

MetLife logo
$84.86 +2.26 (+2.74%)
(As of 12:20 PM ET)

MetLife - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
0
Buy
13

Based on 13 Wall Street analysts who have issued ratings for MetLife in the last 12 months, the stock has a consensus rating of "Buy." Out of the 13 analysts, 13 have given a buy rating for MET.

Consensus Price Target

$88.46
4.24% Upside
According to the 13 analysts' twelve-month price targets for MetLife, the average price target is $88.46. The highest price target for MET is $97.00, while the lowest price target for MET is $80.00. The average price target represents a forecasted upside of 4.24% from the current price of $84.86.
Get the Latest News and Ratings for MET and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for MetLife and its competitors.

Sign Up

MET Analyst Ratings Over Time

TypeCurrent Forecast
11/22/23 to 11/21/24
1 Month Ago
10/23/23 to 10/22/24
3 Months Ago
8/24/23 to 8/23/24
1 Year Ago
11/22/22 to 11/22/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
13 Buy rating(s)
13 Buy rating(s)
12 Buy rating(s)
9 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$88.46$88.46$83.00$75.45
Forecasted Upside4.24% Upside4.35% Upside11.65% Upside19.83% Upside
Consensus Rating
Buy
Buy
Moderate Buy
Moderate Buy

MET Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MET Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

MetLife Stock vs. The Competition

TypeMetLifeFinance CompaniesS&P 500
Consensus Rating Score
3.00
2.49
2.50
Consensus RatingBuyHoldModerate Buy
Predicted Upside8.29% Upside12.92% Upside9.84% Upside
News Sentiment Rating
Positive News

See Recent MET News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/5/2024Wells Fargo & Company
3 of 5 stars
 Boost TargetOverweight ➝ Overweight$92.00 ➝ $93.00+18.53%
10/31/2024Barclays
3 of 5 stars
A. Scott
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOverweight ➝ Overweight$91.00 ➝ $90.00+14.64%
10/9/2024TD Cowen
4 of 5 stars
A. Kligerman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$97.00+16.47%
10/2/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$85.00 ➝ $92.00+12.46%
9/27/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$89.00 ➝ $95.00+14.71%
8/19/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$86.00 ➝ $85.00+15.98%
8/1/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$99.00 ➝ $96.00+24.92%
7/23/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$83.00 ➝ $89.00+18.26%
7/8/2024Keefe, Bruyette & Woods
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$86.00 ➝ $85.00+22.30%
7/2/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$81.00 ➝ $86.00+23.03%
5/22/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$77.00 ➝ $80.00+9.50%
2/5/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$87.00 ➝ $82.00+24.05%
1/8/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$70.00 ➝ $80.00+16.08%
10/4/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold$71.00+18.33%
8/4/2023Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$70.00 ➝ $74.00+14.14%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 12:46 PM ET.


Should I Buy MetLife Stock? MET Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, November 1, 2024. Please send any questions or comments about these MetLife pros and cons to contact@marketbeat.com.

MetLife
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in MetLife, Inc.:

  • MetLife's stock price has been steadily increasing, reaching $82.50 on the latest trading day, indicating positive market sentiment.
  • MetLife has consistently beaten analysts' earnings estimates, showcasing strong financial performance.
  • The company has a solid dividend payout ratio of 74.91%, providing investors with a steady income stream.
  • MetLife's diverse business segments across different regions offer a level of stability and global exposure for investors.
  • Analysts have given MetLife an average rating of "Moderate Buy" with a consensus price target of $85.23, indicating positive outlook from experts.

MetLife
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in MetLife, Inc. for these reasons:

  • MetLife's stock price has recently reached a 1-year high of $82.99, potentially signaling a near-term peak in valuation.
  • The company's PE ratio of 28.46 may indicate that the stock is currently overvalued compared to industry peers.
  • MetLife's debt-to-equity ratio of 0.56 suggests a moderate level of financial leverage, which could pose risks in uncertain economic conditions.
  • The company's revenue for the latest quarter was slightly below analysts' expectations, raising concerns about future growth prospects.
  • Market volatility and regulatory changes in the insurance industry could impact MetLife's profitability and stock performance.

MET Forecast - Frequently Asked Questions

According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for MetLife is $88.46, with a high forecast of $97.00 and a low forecast of $80.00.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MetLife in the last twelve months. There are currently 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MET shares.

According to analysts, MetLife's stock has a predicted upside of 4.24% based on their 12-month stock forecasts.

MetLife has been rated by research analysts at Barclays, Jefferies Financial Group, Piper Sandler, TD Cowen, and Wells Fargo & Company in the past 90 days.

Analysts like MetLife more than other "finance" companies. The consensus rating for MetLife is Buy while the average consensus rating for "finance" companies is Hold. Learn more on how MET compares to other companies.


This page (NYSE:MET) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners